Aeolus' AEOL 10150 Subject of $4.3 Million US Government Award for Protection Against Nerve Agents; Data Shows Drug Significantly Improves Survival in Animals Following Exposure to Pilocarpine, a Nerve Agent Surrogate for Soman and Sarin Gas
11 sept. 2013 12h20 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Sep 11, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) National Institutes of Health - National Institute of Neurological...
Aeolus Announces Third Quarter Fiscal Year 2013 Financial Results
14 août 2013 16h30 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Aug 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company developing compounds to protect against radiological and chemical threats with...
Aeolus' AEOL 10150 Significantly Improves Survival From Nitrogen Mustard Exposure to Skin in Animals
02 juil. 2013 08h00 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jul 2, 2013) - Aeolus Pharmaceuticals (OTCQB: AOLS) Data presented at 6th Annual NIH CounterACT Network Research Symposium ...
Aeolus' AEOL 10150 Significantly Improves Survival in Animals Exposed to Mustard Gas
26 juin 2013 14h02 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - Jun 26, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) Data presented at 7th Annual NIH CounterACT Network Research...
Aeolus Strengthens Board of Directors With Oncology, Government Contracting and Financial Industry Veterans
17 mai 2013 14h19 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 17, 2013) -  Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Pharmaceuticals Announces Second Quarter Fiscal Year 2013 Financial Results
15 mai 2013 14h38 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwired - May 15, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Provides Investor Update on Passage of Pandemic All-Hazards Preparedness Act of 2013
14 mars 2013 08h31 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Mar 14, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) Bill Signed into Law by President Obama Passed Senate...
Aeolus Pharmaceuticals Announces First Quarter Fiscal Year 2013 Financial Results
19 févr. 2013 18h00 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 19, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS) Beginning Third Year of $118.4 Million BARDA Advance Research and...
Aeolus Pharmaceuticals Announces $3.2 Million Private Placement Financing
19 févr. 2013 17h46 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Feb 19, 2013) -  Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...
Aeolus Pharmaceuticals Announces Fiscal Year 2012 Results
02 janv. 2013 10h59 HE | Aeolus Pharmaceuticals
MISSION VIEJO, CA--(Marketwire - Jan 2, 2013) - Aeolus Pharmaceuticals, Inc. (OTCQB: AOLS), a biotechnology company leveraging significant government funding to develop a platform of novel...